{"title":"RETROSPECTIVE ANALYSIS OF THE RESULTS OF SYSTEMIC THERAPY OF MODERATE TO SEVERE PAPULO-PUSTULAR ACNE","authors":"Irina Khismatulina, Еlena Faizullina","doi":"10.25208/vdv5711","DOIUrl":null,"url":null,"abstract":"Background: Systemic isotretinoin is an effective treatment for acne, but the significant relapse rate requires a search for optimal daily doses to prolong disease remission.
 Purpose: To compare the results of systemic therapy of moderate-to-severe resistant and severe papulopustular pustular acne with isotretinoin at daily doses of 0.5; 0.7 and 1.0 mg/kg body weight.
 Methods: In a retrospective study, data from outpatient records and facial skin corneometry results of 125 individuals (95 acne patients, 30 healthy individuals) were analyzed. Patients with acne received isotretinoin (Sotret)at a daily dose of0.5; 0.7 or 1.0 mg/kg body weight, with a cumulative dose of 120 mg/kg body weight in all patients. The duration of follow-up of patients, according to outpatient records, was 18 months.
 Results: Isotretinoin systemic therapy was effective in patients in all compared groups. The resolution of inflammatory elements was faster (p0.001) in those who received doses of isotretinoin 0.7 and 1.0 mg/kg body weight. After treatment, elevated values of sebumetry, skin relief, pore size, and pigmentation were normalized in all groups. There was a significant difference in the incidence of adverse events depending on the dose of isotretinoin. The number of patients with relapses registered at 18-week follow-up after therapy in Group I was 6 (18.75%); in Group II, 4 (12.5%); in Group III, 1 (3.2%), the differences between the groups being significant (p=0.003).
 Conclusion: Therapy of moderate-to-severe resistant and severe papulopustular acne with systemic isotretinoin (Sotret) at daily doses of 0.5; 0.7 and 1.0 mg/kg at a cumulative dose of 120 mg/kg body weight demonstrates comparable clinical efficacy. However, recurrence rates during the 18-month follow-up period correlated with the daily dose of the drug.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"216 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik dermatologii i venerologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25208/vdv5711","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Systemic isotretinoin is an effective treatment for acne, but the significant relapse rate requires a search for optimal daily doses to prolong disease remission.
Purpose: To compare the results of systemic therapy of moderate-to-severe resistant and severe papulopustular pustular acne with isotretinoin at daily doses of 0.5; 0.7 and 1.0 mg/kg body weight.
Methods: In a retrospective study, data from outpatient records and facial skin corneometry results of 125 individuals (95 acne patients, 30 healthy individuals) were analyzed. Patients with acne received isotretinoin (Sotret)at a daily dose of0.5; 0.7 or 1.0 mg/kg body weight, with a cumulative dose of 120 mg/kg body weight in all patients. The duration of follow-up of patients, according to outpatient records, was 18 months.
Results: Isotretinoin systemic therapy was effective in patients in all compared groups. The resolution of inflammatory elements was faster (p0.001) in those who received doses of isotretinoin 0.7 and 1.0 mg/kg body weight. After treatment, elevated values of sebumetry, skin relief, pore size, and pigmentation were normalized in all groups. There was a significant difference in the incidence of adverse events depending on the dose of isotretinoin. The number of patients with relapses registered at 18-week follow-up after therapy in Group I was 6 (18.75%); in Group II, 4 (12.5%); in Group III, 1 (3.2%), the differences between the groups being significant (p=0.003).
Conclusion: Therapy of moderate-to-severe resistant and severe papulopustular acne with systemic isotretinoin (Sotret) at daily doses of 0.5; 0.7 and 1.0 mg/kg at a cumulative dose of 120 mg/kg body weight demonstrates comparable clinical efficacy. However, recurrence rates during the 18-month follow-up period correlated with the daily dose of the drug.